AMIDEX Cancer Innovation & Healthcare
970 Rittenhouse Road Willow Grove, PA 19090
Map
Phone: 888-876-3566
| Category: | Health | | Fund Family: | AMIDEX | | Net Assets: | 830.00K | | Year-to-Date Return: | 4.17% | | Yield: | 0.00% | | Morningstar Rating: |  | | Fund Inception Date: | 01-Nov-01 |
|
Gadi Beer
Lead Manager since
01-Nov-01 | | | Beer is the chief operating officer of Index Investments LLC. He has served as research analyst and vice president since 1999. |
| Min Initial Investment: | $500 | | Min Initial Investment, IRA: | $500 | | Min Initial Investment, AIP: | $500 | | Min Subsequent Investment: | $205 | | Min Subsequent Investment, IRA: | $250 | | Min Subsequent Investment, AIP: | $250 |
|
| |
| The investment seeks long-term growth of capital. The fund usually invests at least 95% of assets in common stocks of companies listed on the AMIDEX-TM- Cancer Innovations & Healthcare index. The Index tracks the performance of publicly traded biotechnology, pharmaceutical and medical equipment companies that emphasize products and services focused on cancer detection and treatment. It employs a passive management approach to invest assets. The fund may also invest in foreign securities that are traded on a U.S. exchange or in a form of American Depository Receipts. The fund is nondiversified. |
| Last Dividend
| YFT_NOT_APPLICABLE_ABBREVIATION | | Last Cap Gain
(29-Dec-08):
| 0.59 | | Annual Holdings Turnover
| .00% | | Average for Category:
| 134.89% |
|
| Expense | CNCRX | Category
Avg | | Total Expense Ratio: | %
| 1.91% | | Max 12b1 Fee: | %
| N/A | | Max Front End Sales Load: | 5.50%
| 5.35% | | Max Deferred Sales Load: | %
| 2.88% | | 3 Yr Expense Projection*: |
$ YFT_NOT_APPLICABLE_ABBREVIATION | $719 | | 5 Yr Expense Projection*: |
$ YFT_NOT_APPLICABLE_ABBREVIATION | $1,076 | | 10 Yr Expense Projection*: |
$ YFT_NOT_APPLICABLE_ABBREVIATION | $2,105 |
|
|
0.30% Nasdaq 
0.02 (0.30%) 
Profile
